Friday, July 4, 2025 7/4/2025

Oklahoma ACE: Molecular Destruction of Autoimmune Disease to Aid Clinical Trail Success

Award Number: UM1AI144292
ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES
OPDIV: NIH
AWARD CLASS: COOPERATIVE AGREEMENT
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 05/01/2019
PERIOD OF PERFORMANCE END DATE: 04/30/2029

Group Awards By:

View Award Description

Oklahoma ACE: Molecular Destruction of Autoimmune Disease to Aid Clinical Trail Success - Project Summary The Oklahoma ACE (OACE) aims to understand autoimmune disease biology through interdisciplinary, collaborative research integrating clinical and basic questions. Prior OACE work as both a Basic and Clinical ACE has significantly advanced our understanding of autoimmune disease genetics, development, flare, and heterogeneity. The OACE has also contributed to eight ACE trials, serving as a Protocol Chair and/or a lead recruitment site for five while also building unique patient cohorts and data/sample collections from diverse urban, rural, and minority communities. Through this UM1 Clinical ACE submission, the OACE strives to deconstruct the molecular heterogeneity of autoimmune disease to implement more effective clinical trial designs, optimize biologically relevant treatment selection, and improve disease understanding. Our primary clinical project builds on our extensive prior work demonstrating a role for EBV reactivation in SLE disease transition, disease activity, and activation of interferon pathways. Utilizing our innovative SLE trial design that provides temporary steroids to allow background immunosuppressants withdrawal, we will test the effectiveness of EBV vaccination in suppressing disease activity and interferon responses in biomarker- selected SLE patients. Partnered mechanistic studies will test the impact of EBV reactivation on autoantibody production and B cell and monocyte activation and function in patients. Preliminary data in our alternate clinical project has found a critical role of the type I IFN pathway in neuromyelitis optica, a complex autoimmune disease with up to 40% of patients have continual relapse and damage even with standard-of- care treatment. We have found that high type I IFN signatures are associated with irreversible disability after an NMO relapse and increased B and Th17 cell signature activation. This first-in-NMO study will assess the effectiveness and safety of the type I IFN receptor antagonist anifrolumab in NMO. Mechanistic studies will determine changes in type I IFN, B cell, and Th17 responses and autoantibody production. Our collaborative project deconstructs molecular heterogeneity and associated pathogenic mechanisms of SLE. Building on preliminary data using multi-omic machine learning to predict abatacept treatment response at baseline, we will distinguish determinants of belimumab treatment in SLE patients initially using deep immunophenotyping, epigenetics, and transcriptomics, evolving to include single-cell technologies as necessary, to capture the biology that determines treatment response. New with this renewal, we propose our OMRF CAP-certified Biorepository to serve as the ACE Biorepository Core, leveraging decades of experience as an autoimmune disease biorepository, dedicated personnel, standard policies/procedures, and high biobanking standards. Our Administrative Core will support an Autoimmune Disease Enrichment Program and Scholars Program and assist with these clinical and collaborative projects. The OACE will also continue to recruit for ACE Network trials and collaborate with other ACE Centers to advance scientific discoveries that improve patient lives.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $767,250 )
2025	2025	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Allergy and Infectious Diseases Research	002	7	5/6/2025	NON-COMPETING CONTINUATION	$767,250
2025	2024	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Allergy and Infectious Diseases Research	001	6	2/19/2025	COMPETING CONTINUATION	$20,984
2025	2023	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Allergy and Infectious Diseases Research	000	5	2/19/2025	NON-COMPETING CONTINUATION	-$20,984
														Subtotal = $767,250

Issue Date FY: 2024 ( Subtotal = $767,250 )
2024	2024	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Allergy and Infectious Diseases Research	000	6	5/1/2024	COMPETING CONTINUATION	$767,250
														Subtotal = $767,250

Issue Date FY: 2023 ( Subtotal = $87,400 )
2023	2023	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Allergy and Infectious Diseases Research	000	5	5/15/2023	NON-COMPETING CONTINUATION	$87,400
														Subtotal = $87,400

Issue Date FY: 2022 ( Subtotal = $87,400 )
2022	2022	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Allergy and Infectious Diseases Research	000	4	4/11/2022	NON-COMPETING CONTINUATION	$87,400
														Subtotal = $87,400

Issue Date FY: 2021 ( Subtotal = $87,400 )
2021	2021	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Allergy and Infectious Diseases Research	000	3	4/22/2021	NON-COMPETING CONTINUATION	$87,400
														Subtotal = $87,400

Issue Date FY: 2020 ( Subtotal = $87,400 )
2020	2020	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Allergy and Infectious Diseases Research	000	2	5/4/2020	NON-COMPETING CONTINUATION	$87,400
														Subtotal = $87,400

Issue Date FY: 2019 ( Subtotal = $262,200 )
2019	2019	OKLAHOMA MEDICAL RESEARCH FOUNDATION	825 NE 13TH ST	OKLAHOMA CITY	OK	73104	OKLAHOMA	USA	Allergy and Infectious Diseases Research	000	1	3/27/2019	NEW	$262,200
														Subtotal = $262,200

Grand Total All Awards = $2,146,300

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Oklahoma ACE: Molecular Destruction of Autoimmune Disease to Aid Clinical Trail Success

Award Number: UM1AI144292

ORGANIZATION: NATIONAL INSTITUTE OF ALLERGY & INFECTIOUS DISEASES

OPDIV: NIH

AWARD CLASS: COOPERATIVE AGREEMENT

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 05/01/2019

PERIOD OF PERFORMANCE END DATE: 04/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer